抗BCMA与抗GPRC5D双特异性抗体治疗多发性骨髓瘤感染风险差异的B细胞亚群选择性耗竭机制
研究通过单细胞RNA测序和流式细胞术发现,抗BCMA双特异性抗体在治疗多发性骨髓瘤时严重耗竭骨髓成熟B细胞和正常浆细胞,并额外耗竭未成熟及小前B细胞,而抗GPRC5D抗体仅靶向浆细胞,这为抗BCMA治疗感染风险增加提供了机制解释。
要点
- 抗BCMA还耗竭未成熟及小前B细胞,而抗GPRC5D仅靶向浆细胞。
- 该机制支持个体化双特异性抗体策略以降低感染风险。
核心结论
- 抗BCMA双特异性抗体靶向浆细胞及小前B阶段起的B细胞,导致感染风险增加。
- 抗GPRC5D双特异性抗体选择性靶向浆细胞,对B细胞亚群影响较小。
研究设计与样本
- 单细胞RNA测序分析11例多发性骨髓瘤患者和8例健康供者的骨髓穿刺样本。
- 下一代流式细胞术免疫分析62例复发多发性骨髓瘤患者。
- 额外流式细胞术(n=31)和单细胞RNA测序(n=8)研究。
- 使用MIcγ1小鼠模型作为B细胞谱系各阶段BCMA表达的阴性对照。
主要发现
- BCMA表达于成熟B细胞及小前B细胞,GPRC5D表达限于恶性及部分正常浆细胞。
- 抗BCMA治疗期间骨髓成熟B细胞从4.9%降至0%(P< .001),正常浆细胞从0.17%降至<0.0002%(P< .001)。
- 抗BCMA还耗竭未成熟和小前B细胞,而抗GPRC5D不耗竭这些亚群。
- MIcγ1小鼠模型抗BCMA治疗后未耗竭任何B细胞亚群。
关键数值与推荐
- 抗BCMA组成熟B细胞下降4.9%至0%(P< .001),正常浆细胞下降0.17%至<0.0002%(P< .001)。
临床怎么用
- 临床选用双特异性抗体时应考虑抗BCMA治疗对B细胞亚群的广泛耗竭及感染风险。
- 支持个体化双特异性抗体策略,可能需加强抗BCMA治疗患者的感染监测。
- 双靶向B细胞和浆细胞策略可能适用于其他B细胞恶性肿瘤或自身免疫病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti-B-cell maturation antigen (BCMA) and anti-G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P< .001), and normal PCs, from 0.17% to <0.0002% (P< .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.
引用
- Jelinek T, Zihala D, Zabaleta A, et al. Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs. Blood. 2026. PMID: 41405507. doi:10.1182/blood.2025029572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。